TrialHIV clinical trials

Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.

Valerianna K Amorosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.